Literature DB >> 1524331

Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis.

G Deray1, M Benhmida, P Le Hoang, P Maksud, B Aupetit, A Baumelou, C Jacobs.   

Abstract

OBJECTIVE: To determine the renal side effects of long-term, low-dose cyclosporine therapy (initial dose, 5 mg/kg body weight per day) in patients with autoimmune idiopathic uvetis.
DESIGN: Cohort study with at least 2 years of follow-up.
SETTING: A teaching hospital in Paris, France (Hôpital Pitié-Salpétrière). PATIENTS: Sixteen patients with idiopathic autoimmune uveitis who were normotensive and had normal renal function before treatment. Cyclosporine was administered orally for at least 2 years at an initial dosage of 5 mg/kg body weight per day.
RESULTS: After 2 years of treatment, the serum creatinine level increased by 35 +/- 5 mumol/L (0.40 +/- 0.06 mg/dL) (95% CI, 25 to 46 mumol/L, [73 +/- 4 to 108 +/- 4 mumol/L]). Creatinine clearance decreased significantly from 120 +/- 5 mL/min to 75 +/- 4 mL/min. Glomerular filtration rate decreased from 116 +/- 8 mL/min to 75 +/- 3 mL/min, and effective renal plasma flow decreased from 455 +/- 24 mL/min to 338 +/- 30 mL/min (P less than 0.05). Cyclosporine induced a significant increase in serum uric acid, total cholesterol, and serum potassium levels. Blood pressure was normal in all patients before treatment; 81% (95% CI, 64% to 98%) of these patients developed hypertension after 24 months of treatment. Blood pressure was controlled with a single drug in all but two patients.
CONCLUSIONS: In patients with healthy native kidneys, long-term cyclosporine therapy, even at a low dose (5 mg/kg per day), is nephrotoxic and is associated with a high incidence of hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524331     DOI: 10.7326/0003-4819-117-7-578

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

Review 1.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 2.  Hypertension after renal transplantation.

Authors:  V Schwenger; M Zeier; E Ritz
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

3.  Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.

Authors:  Kirsten Siepmann; Matthias Huber; Nicole Stübiger; Christoph Deuter; Manfred Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-15       Impact factor: 3.117

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.

Authors:  Minh-Vu H Nguyen; Matthew R Davis; Rebecca Wittenberg; Ian Mchardy; John W Baddley; Brian Y Young; Alex Odermatt; George R Thompson
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

Review 6.  Secondary hypertension: interfering substances.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

7.  Sustained release intraocular drug delivery devices for treatment of uveitis.

Authors:  Nahid Haghjou; Masoud Soheilian; Mohammad Jafar Abdekhodaie
Journal:  J Ophthalmic Vis Res       Date:  2011-10

Review 8.  Electrolyte and Acid-base disturbances induced by clacineurin inhibitors.

Authors:  Chang Hwa Lee; Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2007-12-31

Review 9.  The role of medications and their management in acute kidney injury.

Authors:  Bradford L McDaniel; Michael L Bentley
Journal:  Integr Pharm Res Pract       Date:  2015-05-18

10.  Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital.

Authors:  Rana M Al AdAwi; Zainab Albu-Mahmood; Mohamed Abdelgelil; Hani Abdelaziz; Derek Stewart; Ahmed Awaisu
Journal:  Risk Manag Healthc Policy       Date:  2021-02-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.